Global Implantable Insulin Pump Market to reach USD XX billion by 2027.Global Implantable Insulin Pump Market is valued approximately USD XX billion in 2020 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2021-2027. An implanted insulin pump is a medical device that is permanently implanted into the human body. This insulin pump distributes insulin into the peritoneal cavity, which has a larger number of blood vessels and can absorb insulin more effectively. Insulin pumps that are implanted in the body provide improved treatment options for diabetics. The market is expected to rise due to an increase in the number of people diagnosed with diabetes, as well as increased knowledge of the many insulin therapies available in the implanted insulin pump market. Furthermore, technical developments in implanted insulin pumps, an increase in the incidence of chronic illnesses such as obesity and heart disease, and an increase in demand for home-based therapies for diabetes management and consultation are driving the market forward. Furthermore, an increase in the elderly population, along with an increase in diabetes prevalence, favourable reimbursement policies in the healthcare system, and a surge in R&D efforts aimed at developing innovative implanted insulin pump technologies, all contribute to the market's growth. Government regulations, on the other hand, are projected to stifle market expansion throughout the projection period. High growth potential in developing markets, on the other hand, is projected to provide profitable possibilities throughout the projection period. The World Health Organization (WHO) designated the COVID-19 outbreak a public health emergency of worldwide significance on January 30, 2020. Around 210 nations have been affected by COVID-19. The COVID-19 epidemic has wreaked havoc on nearly every facet of healthcare, including diabetes treatment. In the short and long term, the impact of this pandemic on the market for implanted insulin pumps will give lessons for medical technology firms in other therapeutic areas.
The main regions of Asia Pacific, North America, Europe, Latin America, and the Rest of the World are included in the geographical analysis of the worldwide Implantable Insulin Pump market. Due to an increase in the number of initiatives and increased government investments for overall R&D of implantable insulin pumps, as well as an increase in the number of product approvals, Asia-Pacific presents lucrative opportunities for key players operating in the market. Furthermore, continuous developments in implanted insulin pumps, the availability of sophisticated healthcare systems, and a large increase in demand for advanced healthcare facilities all contribute to the market's growth. Furthermore, leading manufacturers' increased attention on extending their geographical presence in growing Asia-Pacific nations to grab high market share is projected to fuel the region's implanted insulin pump market expansion.
Major market player included in this report are:
Apex Medical
CVS Health (Aetna Inc.)
Diabeloop
Diamesco Co., Ltd
F. Hoffmann La Roche Ltd
Insulet Corporation
Johnson & Johnson
Medtronic Plc
SOOIL Developments Co. Ltd
Tandem Diabetes Care.
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Mode of Operation offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Type:
Closed loop insulin pump
Open loop insulin pump
By Disease:
Type 1 diabetes
Type 2 diabetes
By End-user:
Hospitals
Homecare
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World
Furthermore, years considered for the study are as follows:
Historical year - 2018, 2019
Base year - 2020
Forecast period - 2021 to 2027
Target Audience of the Global Implantable Insulin Pump Market in Market Study:
Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors